Exagen (XGN) Net Income towards Common Stockholders (2018 - 2026)

Exagen has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 5.73% year-over-year to -$4.0 million; the trailing twelve-month figure through Mar 2026 stood at -$20.2 million (down 30.04% YoY), and the FY2025 full-year result was -$20.0 million, down 31.99% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$4.0 million, up from -$4.7 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$3.0 million in Q2 2024, with the low at -$15.1 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$6.5 million across 5 years, with a median of -$5.0 million in 2024.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 128.86% — and 2023, when it surged 65.83%.
• Exagen's Net Income towards Common Stockholders stood at -$15.1 million in 2022, then surged by 63.35% to -$5.5 million in 2023, then jumped by 32.11% to -$3.8 million in 2024, then retreated by 24.25% to -$4.7 million in 2025, then climbed by 15.11% to -$4.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$4.0 million (Q1 2026), -$4.7 million (Q4 2025), and -$7.1 million (Q3 2025), per Business Quant data.